IHI vs XHE

Key Takeaways

• IHI offers market-cap weighted exposure to 47 U.S. medical device companies, with top holdings like ISRG (16.5%) and ABT (16.1%) comprising over 75% of assets, emphasizing large-cap leaders.
• XHE provides modified equal-weighted access to 68 health care equipment firms, capping individual weights at around 2.7% for broader mid- and small-cap participation.
• XHE's expense ratio of 0.35% edges out IHI's 0.38%, offering slight cost efficiency in a concentrated sector.
• IHI demonstrates superior liquidity with average daily volume exceeding 2 million shares versus XHE's under 40,000, reducing trading costs for investors.
• Both ETFs maintain nearly 100% healthcare allocation but differ in risk: IHI's large-cap tilt yields lower volatility, while XHE's equal-weighting amplifies small-cap swings.
• In recent market cycles, XHE has shown relative resilience amid sector pressures, benefiting from diversified holdings.

Introduction

Investors seeking targeted exposure to the U.S. medical devices and health care equipment sector have compelling options in IHI and XHE. These ETFs provide alternative strategies within the same thematic space: IHI focuses on established large-cap innovators via market-cap weighting, while XHE employs a modified equal-weight approach to capture a wider array of mid- and small-cap players. Amid rising demand for advanced diagnostics, robotics, and minimally invasive procedures, comparing their structural differences, cost profiles, and exposure nuances is timely. This analysis highlights how each positions investors in a sector poised for growth driven by aging demographics and technological advancements, yet challenged by regulatory scrutiny and supply chain dynamics.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) is a passively managed fund that tracks the Dow Jones U.S. Select Medical Equipment Index, comprising U.S. equities involved in manufacturing and distributing non-disposable medical devices such as imaging scanners, pacemakers, and prosthetics. Launched in 2006 by BlackRock's iShares, it holds 47 stocks with an expense ratio of 0.38%. Top holdings dominate: ISRG (Intuitive Surgical) at 16.5%, ABT (Abbott Laboratories) at 16.1%, SYK (Stryker) at 11.0%, EW (Edwards Lifesciences) at 5.0%, and IDXX (IDEXX Laboratories) at 4.7%, accounting for over 75% of assets. Sector allocation is nearly 100% healthcare, with a large-cap bias reflected in its weighted average market cap. IHI rebalances periodically to mirror the index, offers high liquidity (average daily volume over 2 million shares), and suits investors favoring concentrated exposure to sector giants.

State Street SPDR S&P Health Care Equipment ETF (XHE) Overview

The State Street SPDR S&P Health Care Equipment ETF (XHE), issued by State Street Global Advisors since 2011, passively tracks the S&P Health Care Equipment Select Industry Index using a modified equal-weighting methodology. This structure limits single-stock influence, holding 68 companies across health care equipment (75%) and supplies (25%), with an expense ratio of 0.35%. Top holdings include STAA (STAAR Surgical) at 2.7%, NVCR (NovoCure) at 2.5%, AXGN (Axogen) at 2.3%, GKOS (Glaukos) at 2.3%, and AVNS (Avanos Medical) at 2.1%, with the top 10 under 21%. Nearly 100% allocated to healthcare, its mid/small-cap tilt enhances diversification. XHE rebalances quarterly to maintain equal weighting, exhibits moderate liquidity (average daily volume around 30,000 shares), and appeals to those seeking broader sector participation beyond mega-caps.

Industry and Thematic Backdrop

The medical devices and health care equipment sector benefits from structural tailwinds including an aging population, AI integration in diagnostics and robotics, and expanding remote patient monitoring. Global market growth is projected above 5% annually, fueled by innovations in minimally invasive procedures and wearables. Capital flows have increased into medtech amid favorable M&A (mergers and acquisitions) environments and venture funding rebounding to multi-year highs in diagnostics and cardiology. Regulatory catalysts like FDA alignment with ISO 13485 standards and CMS expansions for ambulatory surgical centers support outpatient shifts. However, risks persist: supply chain vulnerabilities from tariffs and reshoring costs, pricing pressures from economic buyers, and FDA resource constraints delaying approvals. Macro factors such as interest rate expectations and geopolitical tensions influence procedural volumes and R&D (research and development) spending.

Performance and Positioning Comparison

In recent months, both ETFs have navigated sector headwinds from valuation adjustments and softer procedural demand, with IHI declining around 15% over the past quarter amid its large-cap concentration. XHE has exhibited relative strength, down less than 10% YTD (year-to-date), buoyed by equal-weighting that captured mid-cap resilience during sector rotation away from mega-caps. Over broader cycles, IHI's lower volatility (around 18% annualized three-year standard deviation) stems from stable giants like ISRG and ABT, contrasting XHE's higher swings (beta above 1.3) tied to smaller names. Earnings cycles in robotics and cardiology have supported IHI's positioning, while XHE benefits from diversified exposure amid interest rate sensitivity and commodity trends impacting device manufacturing.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions in dynamic sectors like healthcare equipment. Explore it today to uncover hidden gems aligned with your strategy.

Tickeron AI Verdict

Tickeron’s AI currently favors XHE with moderate conviction (60-70% probability of outperformance over the next quarter). Its lower expense ratio, superior diversification via equal-weighting, and exposure to mid-cap momentum provide structural edges in a sector favoring broader participation amid recent large-cap underperformance. IHI's liquidity and large-cap stability remain attractive for conservative positioning, but XHE aligns better with trend consistency and risk-adjusted potential in prevailing market rotations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations